| By Sun Pharma |
| Wednesday, 18 November 2009 |
 |
Sun Pharmaceutical Industries Ltd. announced that the USFDA has granted its subsidiary an approval for its application for Nicardipine Hydrochloride Injections.
|
|
These Nicardipine Hydrochloride Injections are available as 25 mg/10ml single use ampuls containing 2.5 mg/ml of the drug, and have annual sales of approximately USD 170 million in the US.
These injections are used for the short-term treatment of hypertension when oral therapy is not feasible or not desirable.
|
|
|
About Sun Pharmaceutical Industries Ltd. About Sun Pharmaceutical Industries Ltd.
Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
In India, the company is a leader in niche therapy areas of psychiatry, |
|
neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms.
Want to read more?
ExxonMobil Celebrates China’s Fujian Facility Completion
The USD 3.2 Billion North American Performance Minerals Market Expected to Rebound from Current Economic Downfall by 2012
Pharma and Biotech Leaders to Converge in Shanghai |
|
|
